Trial reportMedical oncology (Northwood, London, England)2015
Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone.
Trial report in Medical oncology (Northwood, London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02455843 (A Multicenter, Randomized, Open-label Phase III Trial of Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized, Open-label Phase III Trial of Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Microwave Ablation Combined With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced Non-Small Cell Lung Cancer-Systematic Review and Meta-Analysis.Thoracic cancer · 2026Pooled it
- The efficacy and safety of thermal ablation for patients with lung malignancy: a meta-analysis of 12 studies in China.Journal of cardiothoracic surgery · 2022Pooled it
- A prognostic model for predicting progression-free survival in patients with advanced non-small cell lung cancer after image-guided microwave ablation plus chemotherapy.European radiology · 2023Trial
- Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.European radiology · 2020Trial
- Trial
- Comparative safety and efficacy of single-agent chemotherapy combined with microwave ablation versus radioactive seed brachytherapy in elderly patients with advanced NSCLC: a ten-year retrospective study.American journal of cancer research · 2025Article
- A retrospective study comparing the efficacy of microwave ablation and stereotactic body radiotherapy in colorectal cancer lung metastases.Oncology letters · 2024Article
- Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report.Translational lung cancer research · 2022Article
- Image-guided percutaneous ablation for lung malignancies.Frontiers in oncology · 2022Review
- Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer.Frontiers in oncology · 2022Article
- Survival benefit of thermal ablation therapy for patients with stage II-III non-small cell lung cancer: A propensity-matched analysis.Frontiers in oncology · 2022Article
- Local ablative therapies in oligometastatic NSCLC-upfront or outback?-a narrative review.Translational lung cancer research · 2021Review
- [Advances and Challenges of Local Thermal Ablation in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Review
- Comparing cryoablation and microwave ablation for the treatment of patients with stage IIIB/IV non-small cell lung cancer.Oncology letters · 2020Article
- Microwave ablation combined with chemotherapy improved progression free survival of IV stage lung adenocarcinoma patients compared with chemotherapy alone.Thoracic cancer · 2019Article
- Transvenous pulmonary chemoembolization (TPCE) for palliative or neoadjuvant treatment of lung metastases.European radiology · 2019Observational
- Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations.Oncotarget · 2017Article
- [Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors (2017 Edition)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2017Article
- Advanced non small cell lung cancer: response to microwave ablation and EGFR Status.European radiology · 2017Article
- Treatment of lung tumours with high-energy microwave ablation: a single-centre experience.Medical oncology (Northwood, London, England) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to determine survival benefit of the microwave ablation (MWA)/chemotherapy combination compared with chemotherapy alone. Patients with untreated, stage IIIB or IV NSCLC and at least one additional measurable site other than the ablative site were enrolled. They were divided into MWA/chemotherapy group and chemotherapy group. The primary endpoint was progression-free survival (PFS); secondary endpoints included response, time to local progression (TTLP), overall survival (OS), and adverse events (AEs). Forty-six and twenty-eight patients were enrolled in the MWA/chemotherapy group and chemotherapy group, respectively. Complete ablation was observed in 84.8 % patients in the MWA/chemotherapy group. Median TTLP was 27.0 months. Objective response rate and disease control rate in MWA/chemotherapy group were 21.7 and 76.1 %, and in the chemotherapy group were 32.1 % (p = 0.320) and 75.0 % (p = 0.916), respectively. MWA/chemotherapy combination prolonged PFS [MWA/chemotherapy group 10.9 (95 % CI 5.1-16.7) ms vs. chemotherapy group 4.8 (95 % CI 3.9-5.8) ms, p = 0.001] and tended to improve OS [MWA/chemotherapy group 23.9 (95 % CI 15.2-32.6) ms vs. chemotherapy group 17.3 (95 % CI 15.2-19.3) ms, p = 0.140]. Multivariate analyses showed that MWA was an independent prognostic factor of PFS and primary tumor size was an independent prognostic factor of OS. AEs of MWA were observed in 67.4 % patients. Chemotherapy-associated AEs were observed in 39.1 and 53.6 % of patients in the MWA/chemotherapy and chemotherapy group, respectively. MWA/chemotherapy combination improved PFS of advanced NSCLC compared to chemotherapy alone, and the combination did not increase the adverse events of chemotherapy.
Indexed as
Identifiers
25572816What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.